Study Summary
This trial is testing a new drug, APG-115, to see if it is safe and effective in treating patients with relapsed or refractory leukemia.
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 28 days
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
APG-115 monotherapy
1 of 2
APG-115 + 5-azacitidine combination
1 of 2
Experimental Treatment
69 Total Participants · 2 Treatment Groups
Primary Treatment: APG-115 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many centers are actively managing this research initiative?
"This medical trial is being conducted across 9 locations, such as the Duke University in Durham and the Texas Oncology - Baylor Charles A. Sammons Cancer Center located in Dallas, TX. There are also other sites like Banner MD Anderson Cancer Centre based in Gilbert." - Anonymous Online Contributor
Is enrollment in this experiment open to the public?
"Indeed, the details posted on clinicaltrials.gov verify that this investigation is actively recruiting participants. This study was initially publicised on December 4th 2020 and amended most recently on July 8th 2022; it requires 69 test subjects from 9 medical centres." - Anonymous Online Contributor
Are there any precedent studies that have used APG-115?
"APG-115 was first researched in 2006 at the Chinese University of Hong Kong-Prince of Wales Hospital. So far, 161 clinical trials have been completed and 174 are currently ongoing with a significant portion occurring in Durham, North Carolina." - Anonymous Online Contributor
What is the current enrollment rate of this clinical trial?
"To fulfil the requirements of this research project, 69 participants that meet set inclusion criteria must be recruited. Patients have access to trial sites such as Duke University in Durham and Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas for their participation." - Anonymous Online Contributor
What maladies are typically addressed by the administration of APG-115?
"APG-115 is generally prescribed for malignant neoplasms, but has also been validated to treat 20-30% blasts, neutropenia and/or thrombocytopenia, anemia." - Anonymous Online Contributor